Discretionary denials at the Patent Trial and Appeal Board, the CRISPR landscape and section 101 are top of mind for Eldora Ellison, director at Sterne Kessler Goldstein & Fox.
Swiss pharmaceutical company Roche will pay $350 million for the rights to develop and distribute an investigational COVID-19 antiviral outside of the US.
Talks on a landmark proposal to waive IP rights for vaccines and treatments related to COVID-19 have stalled, following the failure of the World Trade Organisation to conclude an agreement.
The English High Court has concluded that Merck Sharp Dohme is not infringing a patent owned by Pfizer through the sale of its pneumococcal conjugate vaccine.
Kilpatrick Townsend & Stockton has strengthened its life sciences expertise with the addition of a patent litigation team, that includes four litigators from DLA Piper.
A unit belonging to German company Braun has allegedly infringed five patents relating to artificial joints for knee and hip replacements, according to a complaint filed by the Orthopaedic Institute for Children.
Biopharmaceutical company, Moderna, has announced that it will not enforce patents related to its COVID-19 vaccine while the pandemic is ongoing, and that it is prepared to license the patents to others after the pandemic is over.
South Africa and India have asked the World Trade Organization to cede some stipulations governing IP so that treatments to combat COVID-19 can become more widely available, particularly in low-income countries.
Regeneron Pharmaceuticals is facing claims that its “antibody cocktail”, which was administered to President Donald Trump to treat his COVID-19 symptoms, was developed with the unauthorised use of a fluorescent protein.
Bristol Myers Squibb has announced it will acquire biotech firm MyoKardia for $13.1 billion, strengthening its portfolio of heart disease treatments.